STOCK TITAN
  1. Home
  2. News
  3. FHTX

Foghorn Therapeutics Inc - FHTX STOCK NEWS

Welcome to our dedicated news page for Foghorn Therapeutics (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Foghorn Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Foghorn Therapeutics's position in the market.

News
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
Rhea-AI Summary
Foghorn Therapeutics appoints Kristian Humer as Chief Financial Officer, bringing over 20 years of financial industry experience to lead the company's financial strategy and business development. Humer's expertise in capital markets and global financial transactions will help position Foghorn for success as they approach critical milestones in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
management
-
News
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Rhea-AI Summary
Foghorn Therapeutics Inc. announces positive preclinical data for potential first-in-class medicines, including FHD-909, at the 2024 AACR Annual Meeting. IND filing for FHD-909 on track for Q2 2024. Conference call scheduled for further pipeline updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
clinical trial
-
News
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
Rhea-AI Summary
Foghorn Therapeutics Inc. (FHTX) to present at the 23rd Annual Needham Virtual Healthcare Conference, showcasing their Gene Traffic Control® platform for treating serious diseases through correcting abnormal gene expression. The company's management will participate in a fireside chat on April 11th, with a focus on oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
conferences
News
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Rhea-AI Summary
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
conferences
-
News
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
Rhea-AI Summary
Foghorn Therapeutics Inc. provided an update on the progress of its clinical studies and preclinical programs, highlighting key milestones for its innovative precision medicine platform. The company's financials show a strong cash position, with significant collaboration revenues and controlled expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
News
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
Rhea-AI Summary
Foghorn Therapeutics Inc. announces the presentation of preclinical data for its pipeline programs at the 2024 AACR Annual Meeting, including FHD-909, a potential first-in-class BRM selective inhibitor. The data showcases significant progress in developing novel medicines targeting the chromatin regulatory system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
conferences clinical trial
News
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
Rhea-AI Summary
Foghorn Therapeutics Inc. (Nasdaq: FHTX) to participate in Cowen’s 44th Annual Health Care Conference, showcasing its Gene Traffic Control® platform in oncology with potential to impact various diseases. The company's Chief Medical Officer will present on March 4, 2024, at 12:50 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.06%
Tags
conferences
-
News
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
Rhea-AI Summary
Foghorn® Therapeutics Inc. (Nasdaq: FHTX) announced that Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development targeting BRG1 mutated non-small cell lung cancer. This collaboration is part of a strategic agreement with Lilly for the development of novel oncology medicines and includes a 50/50 co-development and co-commercialization agreement for Foghorn’s Selective BRM oncology program and an additional undisclosed oncology target.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.45%
Tags
none
-
News
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
Rhea-AI Summary
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announces strategic objectives for 2024, including progress in AML combination study, preclinical data for FHD-286 and tyrosine kinase inhibitors, partnership with Loxo@Lilly, and IND filings. The company holds $259.9 million in cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.38%
Tags
none
News
Foghorn Therapeutics Announces CFO Departure
Rhea-AI Summary
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced the departure of Chief Financial Officer, Allan Reine, to pursue another opportunity. The company is now searching for a successor. Dr. Reine's last day will be January 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
none
Stock FHTX logo
Foghorn Therapeutics Inc

Nasdaq:FHTX

FHTX Rankings

#3612 Ranked by Market Cap
#4945 Ranked by Stock Gains
N/A Ranked by Dividends

FHTX Stock Data

315.84M
21.35M
24.79%
61.83%
2.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Cambridge

About FHTX

foghorn therapeutics inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. the company uses its proprietary gene traffic control platform to identify, validate, and potentially drug targets within the system. it is developing fhd-286, a small-molecule enzymatic inhibitor of brg1 and brm for the treatment of acute myeloid leukemia and uveal melanoma; and fhd-609, a small molecule protein degrader of brd9 to treat patients with synovial sarcoma. the company is also developing preclinical and discovery programs, including selective brm targeting non-small-cell lung cancer; and selective arid1b modulators for bladder, ovarian, and endometrial cancer. it has a collaboration with merck sharp & dohme corp. to discover and develop novel oncology therapeutics against a transcription factor target. the company was founded in 2015 and is headquartered in cambridge, massachusetts.